Previous 10 | Next 10 |
Shares of Amarin (NASDAQ: AMRN) jumped by as much as 11.7% in pre-market trading Monday morning. What's driving this sizable move higher ahead of the opening bell? On Friday, Amarin announced that the Food and Drug Administration had approved Vascepa as an add-on to statin therapy in patien...
VASCEPA becomes the first and only FDA-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in high-risk patients approved for treatment Millions of people in the United States qualify as treatment candidates for VASCEPA Cardiovascula...
As expected, the FDA approves a cardiovascular (CV) benefit claim for Amarin's (NASDAQ: AMRN ) Vascepa (icosapent ethyl) based on results from the large-scale REDUCE-IT study. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, Read more ...
While the world of biotech has always been an interesting one, now's an especially exciting time to consider investing in the sector. There are many potential blockbuster drugs awaiting U.S. Food and Drug Administration (FDA) approval, with a number of treatments having already received a thum...
Buyout mania has definitely taken over the biopharma industry lately. With the year winding down, we've witnessed numerous transactions in the space at absolutely gobsmacking premiums. Here is a brief overview of the biggest deals over the past two months. Best of all, this trend should ...
Amarin ( AMRN ) has been quite the fighter when it comes to litigating for their rights. Not only has it sued all manners of generic companies all over the world, who have come attacking as soon as they discovered the promise of Vascepa, but Amarin has even had to sue the FDA, and win. This wi...
Allakos ( ALLK ) was up a whopping 40% in a day's trading on 8x surge in volume on Friday on what has been called "sales chatter." I covered ALLK in August in a mostly bearish article after it almost tripled overnight after results from a Phase 2 study of lead candidate AK002 was publis...
A number of biotech companies are awaiting responses from the U.S. Food and Drug Administration (FDA) this month. If granted approval from the agency, it wouldn't be surprising if many of these stocks see a big jump following the news. While many drug candidates will receive a response from t...
Biotech investors know that simply generating some positive clinical trial data for a candidate treatment is no guarantee that the drug will make it to market. The U.S. Food and Drug Administration (FDA) looks deep before giving its approval. And when a company announces that it has received e...
Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...